Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7)
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In patients with type 2 dibetes and moderate‐to‐severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine‐based eGFR can be altered independently of kidney function. Cystatin C‐based eGFR is not affected by muscle mass. The objective of this post‐hoc analysis was to determine whether the lesser eGFR decline with dulaglutide was related to BW loss. Baseline characteristics were similar between treatments ([mean ± SD] age, 64.6 ± 8.6 years; women, 48%; BW, 89.1 ± 17.7 kg; eGFR [CKD‐EPI‐cystatin C] 38 ± 14 mL/min/1.73m 2 ). BW decreased with dulaglutide 1.5 and 0.75 mg and increased with insulin glargine ([LSM change (SE)], −2.66 [0.47] kg and −1.71 [0.45] vs 1.57 [0.43] kg; P < 0.001). Changes in eGFR were not significant with dulaglutide 1.5 and 0.75 mg, but eGFR significantly decreased with insulin glargine (eGFR‐CKD‐EPI‐cystatin C [LSM change (95%CI)], −0.7 [−2.5, 1.0] and −0.7 [−2.4, 1.1] vs −3.3 [−5.1, −1.6] mL/min/1.73 m 2 ; P ≤ 0.037 vs glargine). Changes in BW did not correlate with changes in eGFR‐CKD‐EPI‐cystatin C (r = −0.041; n = 471; P = 0.379) or eGFR‐CKD‐EPI‐creatinine (r = −0.074; n = 473; P = 0.106). In conclusion, the lesser decline in eGFR observed with dulaglutide was not influenced by BW loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336 · cited 1×
“GLP-1 has been shown to produce anti-inflammatory effects, amelioration of oxidative stress and vascular endothelium protection in pre-clinical models of diabetic kidney disease.(11,12) Serum creatinine levels are influenced by changes in BW if muscle”
BackgroundJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Self-citation
Research works printed but not linked: 11
- Davies M, 2016, The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies, Clin Pharmacol, 8, 61
- 10.1053/j.ajkd.2014.08.001 · DOI · Paper page
- 10.1186/s12882-017-0474-0 · DOI · Paper page
- 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
- 10.7326/0003-4819-150-9-200905050-00006 · DOI · Paper page
- 10.1159/000180580 · DOI · Paper page
- 10.2165/00003088-200544100-00004 · DOI · Paper page
- 10.1038/ki.2014.236 · DOI
- 10.1016/j.jdiacomp.2015.08.007 · DOI
- 10.1038/oby.2009.96 · DOI · Paper page
- 10.2215/CJN.02490508 · DOI · Paper page
Cited by
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Self-citationShaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationHeerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0261 · Cited by 53
Self-citation
Metadata
- Authors
- Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Zimmermann, A. G., Woodward, B., & Botros, F. T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2019-03-29
- Volume
- 21
- Issue
- 6
- Pages
- 1493-1497
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2911578171
- Cited by
- 42
- References
- 7
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7). https://app.cochat.ai/papers/10.1111/dom.13668
- The paper
- Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Zimmermann, A. G., Woodward, B., & Botros, F. T. (2019). Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate‐to‐severe chronic kidney disease (AWARD‐7). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13668
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.